Loading…
Evidence for in Vivo Scavenging by Aminoguanidine of Formaldehyde Produced via Semicarbazide-Sensitive Amine Oxidase-Mediated Deamination
Aminoguanidine (AG) is capable of preventing advanced protein glycation and inhibiting the activity of enzymes with carbonyl groups as cofactors, such as nitric-oxide synthase (NOS) and semicarbazide-sensitive amine oxidase (SSAO). The hydrazide moiety of AG can also interact with different endogeno...
Saved in:
Published in: | The Journal of pharmacology and experimental therapeutics 2007-09, Vol.322 (3), p.1201-1207 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Aminoguanidine (AG) is capable of preventing advanced protein glycation and inhibiting the activity of enzymes with carbonyl
groups as cofactors, such as nitric-oxide synthase (NOS) and semicarbazide-sensitive amine oxidase (SSAO). The hydrazide moiety
of AG can also interact with different endogenous carbonyl metabolites and potentially harmful endogenous aldehydes. Aldehydes
can be generated via different pathways, such as lipid peroxidation (malondialdehyde and 4-hydroxynonenal), oxidative deamination
(aldehydes), and carbohydrate metabolism (methylglyoxal). Formaldehyde and methylglyoxal are produced via SSAO-catalyzed deamination
of methylamine and aminoacetone, respectively. An increase in SSAO-mediated deamination is known to be associated with various
vascular disorders, such as diabetic complications. The present study demonstrates that AG is not only capable of rapidly
interacting with aldehydes in vitro but also scavenging aldehydes in vivo. The AG-formaldehyde adducts were traced, and their
structures were elucidated by high-performance liquid chromatography-mass spectrometry. AG has also been shown to block formaldehyde-induced
β-amyloid aggregation. Thus, AG can be an aldehyde scavenger in addition to blocking advanced glycation and inhibition of
SSAO and NOS activity. Such reactions may contribute to its pharmacological effects in the treatment of vascular disorders
associated with diabetic complications and other disorders. |
---|---|
ISSN: | 0022-3565 1521-0103 |
DOI: | 10.1124/jpet.107.124123 |